Related Experiment Videos
Atiprimod (AnorMED)
1Drug Safety Evaluation Consulting Inc, 441 Green Glade Road, Birmingham, AL 35244, USA. Dblakings@aol.com
Idrugs : the Investigational Drugs Journal
|August 17, 2005
Summary
Atiprimod, an oral cytokine inhibitor targeting macrophages, shows promise for treating rheumatoid arthritis and autoimmune diseases. AnorMED is seeking partners for further development after successful Phase I and FDA-approved Phase II trials.
Area of Science:
- Immunology
- Pharmacology
- Rheumatology
Background:
- Atiprimod is an oral cytokine inhibitor targeting macrophages.
- It is being developed for rheumatoid arthritis and other autoimmune diseases.
Purpose of the Study:
- To summarize the development status and potential of atiprimod.
- To highlight AnorMED's search for corporate partners for further advancement.
Main Methods:
- Phase I trials completed successfully.
- Phase II multicenter trials approved by the FDA.
- Synthesis described in European patent EP-00310321.
Main Results:
- Successful completion of Phase I trials.
- FDA approval for Phase II multicenter trials.
- SmithKline Beecham discontinued development due to restructuring.
Conclusions:
- Atiprimod demonstrates potential as a treatment for autoimmune conditions.
- AnorMED holds all rights and is seeking partners for continued development.